Drug Profile
Research programme: protein therapeutics - Gyre Therapeutics/Merck
Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator GNI; Organon; Shanghai Genomics
- Developer Gyre Therapeutics; Schering-Plough
- Class Proteins
- Mechanism of Action Steroid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atherosclerosis; Cancer; Rheumatoid arthritis
Most Recent Events
- 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
- 31 Dec 2009 No development reported - Preclinical for Atherosclerosis in China (unspecified route)
- 31 Dec 2009 No development reported - Preclinical for Cancer in China (unspecified route)